Jonsson, Malin K B <br/><br/>
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.  [electronic resource] 

 -  Journal of molecular and cellular cardiology  May 2012 
 - 998-1008 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-8584 
<br/><br/><label>Standard No.: </label>10.1016/j.yjmcc.2012.02.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester--pharmacology<br/>Action Potentials<br/>Arrhythmias, Cardiac--drug therapy<br/>Benzazepines--pharmacology<br/>Calcium Channel Agonists--pharmacology<br/>Calcium Channel Blockers--pharmacology<br/>Calcium Signaling<br/>Cells, Cultured<br/>Cisapride--pharmacology<br/>Drug Evaluation, Preclinical<br/>ERG1 Potassium Channel<br/>Embryonic Stem Cells--physiology<br/>Ether-A-Go-Go Potassium Channels--antagonists & inhibitors<br/>Humans<br/>Myocytes, Cardiac--drug effects<br/>Nifedipine--pharmacology<br/>Patch-Clamp Techniques<br/>Sodium Channels--metabolism